Altimmune, Inc. (ALT) financial statements (2020 and earlier)

Company profile

Business Address 910 CLOPPER ROAD
GAITHERSBURG, MD 20878
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments37349221161910
Cash and cash equivalents9349154161910
Short-term investments28  67   
Restricted cash and investments014    
Receivables2410  04
Other undisclosed current assets0111200
Total current assets:393923222171914
Noncurrent Assets
Operating lease, right-of-use asset1
Property, plant and equipment1110000
Intangible assets, net (including goodwill)1314392222
Goodwill   2222
Intangible assets, net (excluding goodwill)131439    
Other noncurrent assets000 000
Total noncurrent assets:1515402333
TOTAL ASSETS:545563225202217
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities444201101
Accounts payable0001101
Accrued liabilities44400  
Taxes payable   3   
Interest and dividends payable   197   
Debt 00  12
Derivative instruments and hedges, liabilities   1000
Restructuring reserve   00 
Deferred revenue and credits0    
Other liabilities   00  
Other undisclosed current liabilities   2114
Total current liabilities:454205237
Noncurrent Liabilities
Long-term debt and lease obligation225   1
Long-term debt, excluding current maturities225   1
Liabilities, other than long-term debt3060123
Accounts payable and accrued liabilities     11
Deferred tax liabilities, net06    
Restructuring reserve    0  
Other liabilities   0001
Business combination, contingent consideration, liability3     
Derivative instruments and hedges, liabilities    012
Other undisclosed noncurrent liabilities     (1)(1)
Total noncurrent liabilities:52110113
Total liabilities:96142053410
Stockholders' equity
Stockholders' equity attributable to parent4648391917187
Common stock0000000
Additional paid in capital18817012249240239218
Accumulated other comprehensive loss(5)(5)(5)(0) (0)(0)
Accumulated deficit(137)(117)(78)(30)(224)(220)(210)
Other undisclosed stockholders' equity  9    
Total stockholders' equity:4648491917187
TOTAL LIABILITIES AND EQUITY:545563225202217

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues610115111018
Revenue, net115111018
Cost of revenue
(Cost of Goods and Services Sold)
    (0)(0)(0)
Gross profit:610115101018
Operating expenses(27)(53)(63)(16)(14)(20)(29)
Other undisclosed operating income    000
Operating loss:(21)(43)(52)(11)(3)(10)(11)
Nonoperating income (expense)1(2)(0)21600(1)
Investment income, nonoperating100   0
Other nonoperating income (expense)00000(0)(0)
Interest and debt expense(0)(0)(0) (0)(0)(0)
Other undisclosed income from continuing operations before equity method investments, income taxes    000
Income (loss) from continuing operations before equity method investments, income taxes:(21)(46)(52)205(3)(10)(12)
Other undisclosed income from continuing operations before income taxes000    
Income (loss) from continuing operations before income taxes:(21)(45)(52)205(3)(10)(12)
Income tax expense (benefit)066(11)(0)(0)(0)
Net income (loss) attributable to parent:(21)(39)(46)194(3)(10)(12)
Preferred stock dividends and other adjustments(0)(3)(5)    
Net income (loss) available to common stockholders, diluted:(21)(42)(51)194(3)(10)(12)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net income (loss):(21)(39)(46)194(3)(10)(12)
Other comprehensive income (loss)  3  (10)(12)
Other undisclosed comprehensive income0      
Comprehensive income (loss):(21)(39)(43)194(3)(20)(23)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent (0) (0)0  
Comprehensive income (loss), net of tax, attributable to parent:(21)(40)(43)194(3)(20)(23)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: